Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study.

BACKGROUND Tamoxifen's cost-benefit ratio for breast ductal intraepithelial neoplasia (DIN) is unclear. Since low-dose tamoxifen showed a favorable modulation of breast cancer biomarkers in phase II trials, a monoinstitutional cohort of women with DIN treated with low-dose tamoxifen or no systemic treatment was analyzed. PATIENTS AND METHODS A total of 309 patients with DIN received low-dose tamoxifen as part of institutional guidelines and were compared with 371 patients with DIN who received no systemic treatment after surgery. RESULTS Women with estrogen receptor (ER)/progesterone receptor (PgR) >50% DIN who were not treated had a higher incidence of breast events than women on tamoxifen [hazard ratio (HR) 1.76; 95% confidence interval (CI) 1.00-3.12] or women with ER/PgR <50% DIN (HR 1.72; 95% CI 1.14-2.58). Among untreated patients with ER >50% DIN, recurrence was higher in PgR > or =50% DIN than in PgR <50% DIN, whereas it was similar among low PgR (<50%) DIN against which tamoxifen had no effect. No difference in endometrial cancer incidence was noted. CONCLUSIONS High ER and especially high PgR expression is a significant adverse prognostic indicator of DIN, and low-dose tamoxifen appears to be an active treatment. Women with low-expression ER or PgR DIN do not seem to benefit from tamoxifen. A definitive clinical trial is warranted.

[1]  A. Luini,et al.  Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years. , 2009, The oncologist.

[2]  R. Swaby,et al.  Young age is not associated with increased local recurrence for DCIS treated by breast‐conserving surgery and radiation , 2008, Journal of surgical oncology.

[3]  Jack Cuzick,et al.  Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Wobbes,et al.  Local recurrences after different treatment strategies for ductal carcinoma in situ of the breast: a population-based study in the East Netherlands. , 2007, International journal of radiation oncology, biology, physics.

[5]  M. Cazzaniga,et al.  Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Jukka Corander,et al.  CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure , 2007, Pharmacogenetics and genomics.

[7]  L. Koniaris,et al.  Results of 23,810 Cases of Ductal Carcinoma-in-situ , 2007, Annals of Surgical Oncology.

[8]  B. Bonanni,et al.  Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Umberto Veronesi,et al.  Rethinking TNM: breast cancer TNM classification for treatment decision-making and research. , 2006, Breast.

[10]  A. Bhatnagar.  Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting. , 2006, Breast.

[11]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[13]  A. Roddam.  Analysing Survival Data from Clinical Trials and Observational Studies , 2005 .

[14]  J. Houghton.  Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial , 2003, The Lancet.

[15]  A. Luini,et al.  A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. , 2003, Journal of the National Cancer Institute.

[16]  C. Osborne,et al.  Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J Cuzick,et al.  Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.

[18]  Andrew Kramar,et al.  Progesterone Receptor Quantification as a Strong Prognostic Determinant in Postmenopausal Breast Cancer Women under Tamoxifen Therapy , 2002, Breast Cancer Research and Treatment.

[19]  C. Lemanski,et al.  Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. , 2002, International journal of radiation oncology, biology, physics.

[20]  N. Rotmensz,et al.  The Italian Breast Cancer Prevention Trial with Tamoxifen , 2001, Annals of the New York Academy of Sciences.

[21]  V. Stern,et al.  Problems in Prisons Worldwide, with a Particular Focus on Russia , 2001, Annals of the New York Academy of Sciences.

[22]  R. Gelber,et al.  Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? , 2000, The Lancet.

[23]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[24]  James Dignam,et al.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial , 1999, The Lancet.

[25]  A. Figer,et al.  Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients , 1999, Breast Cancer Research and Treatment.

[26]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[27]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[28]  G. Contesso,et al.  Is the negative prognostic value of high oestrogen receptor (ER) levels in postmenopausal breast cancer patients due to a modified ER gene product? , 1995, European journal of cancer.

[29]  W. McGuire,et al.  Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Peterse,et al.  Clinical Outcome after Selective Treatment of Patients Diagnosed with Ductal Carcinoma In Situ of the Breast , 2007, Annals of Surgical Oncology.

[31]  David A. Flockhart,et al.  The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen , 2006, Breast Cancer Research and Treatment.

[32]  M. Cazzaniga,et al.  Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  I. Christensen,et al.  Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. , 1993, European journal of cancer.